Meanwhile, it has been reported, that APOA2 bears different types of PTM (phosphorylation and acetylation) within initiation center of APOA2 homodimerization in patients with breast and ovarian cancer (Table 4), which meaningfully prevents proper functioning and embedding of APOA2 into HDL particles. This evidence concerns the gene APOA2 and ovarian cancer.